Objectives: Precise monitoring of haemostasis is of utmost importance in ventricular assist device recipients. In clinical routine thromboplastin time (PTT) and international normalized ratio (INR) are used for evaluation of coagulation capacity and adjustment of anticoagulation therapy. In detail, PTT represents endogenous homeostasis and INR represents the exogenous homeostasis but both only reflect 2 percentage of the total plasmatic thrombin generation. During the past decade alternative methodological approaches were designed to address the total thrombin generation (TG) as a measure for true plasmatic coagulation. The present study aimed to investigate the course of thrombin generation in VAD recipients in intensive care unit. Furthermore, the study reveals a more detailed few of the disturbed haemostasis and its correlation with bleeding and thromboembolism events. Methods: Thrombin generation was measured in platelet-poor (PPP) and platelet rich plasma (PRP) from 20 healthy controls and 15 left ventricular assist device (LVAD) recipients 4 weeks postoperatively over a period of 10 days. Samples were taken 4 times per day, while this was done only once per day in healthy controls. Clinical data including clotting tests (partial thromboplastin time, prothrombin time and its derived measures of international normalized ratio) were also collected at the same time points. Results: Analyzing PRP, endogenous thrombin potential (ETP) was significant different (p < 0.001) comparing LVAD recipients (AUC: 1046 ± 149 nmol/l*min) and controls (AUC: 2601 ± 320 nmol/l*min) regarding peak thrombin (110.5 ± 32 nmol/l; 242.9 ± 48.1 nmol/l), lag time (4.5 ± 1.1 minute; 3.1 ± 0.5 minute) and time to thrombin peak (15.2 ± 2.1 minute; 7.2 ± 1.9 minute). Three recipients showed bleeding events (1–15 days). Additionally, there was no significant difference in thrombin generation comparing PPP versus PRP in LVAD recipients, indicating diminished platelet function. Additionally, no correlation between PTT or prothrombin time and bleeding events was observed, while ETP was significantly down-regulated (−75± 3% of controls) in LVAD recipients. Conclusion: Monitoring of TG identify bleeding events in LVAD recipients and have a prognostic value. Moreover, the PPP/PRP ratio displayed physiological dysfunction of platelet.

Background: The inverse association between HDL‐cholesterol (HDL‐C) levels and the risk of cardiovascular diseases is evident. Hypothesis: Our hypothesis was that higher levels of HDL‐C predisposed patients with coronary artery disease (CAD) to chronic coronary syndromes (CCS) rather than acute coronary syndrome (ACS), which has not clearly been demonstrated yet. Aim: To determine, in an unselected population of patients treated with percutaneous coronary intervention (PCI), if HDL‐C levels are independently higher in subjects presenting with CCS compared with those with ACS. Methods and Results: In this retrospective study, we identified 4215 patients who underwent PCI in the Cardio‐FR database. A total of 2942 patients met the selection criteria and completed at least a 1‐year follow‐up: 1686 suffered an ACS whereas 1256 presented with CCS. We found that low HDL‐C levels were significantly associated with ACS and high HDL‐C levels with CCS. This was consistent across all BMI categories in both genders. In addition, higher HDL‐C levels reduced the likelihood of CAD subjects developing ACS. Specifically, each mmol/L increase in HDL‐C decreased the odds of ACS by 79%. Interestingly, the CCS group had more polymorbid subjects than the ACS group. At 2‐year follow‐up, no difference in patient‐oriented composite endpoint was seen between high and low HDL‐C groups. Conclusion: In an unselected population of coronary patients, HDL‐C levels were consistently lower in individuals presenting with ACS compared with CCS, independently of BMI and gender. This finding strengthens the hypothesis that HDL‐C plays a role in long‐term protection against atherosclerotic plaque vulnerability. Considering HDL‐C level still makes sense. Trial Registration: ClinicalTrials.gov identifier: NCT04185285